Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.

Thompson RG, Pearson L, Kolterman OG

Diabetologia1 Nov 1997Cited by 32 (Europe PMC)

PMID9389419DOI10.1007/s001250050821PepBankPUB-09389419

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with IDDM, hypoglycaemia incidence did not differ between any pramlintide group and placebo.
In plain wordsIn patients with IDDM, low blood sugar occurred at similar rates with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycaemia
Study
n = 215
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
30 microg four times per day; 30 microg three times per day (BLD or BDS); 60 microg twice per day · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycaemia was not different in any pramlintide group compared to the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial.
Summary · context
Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 microg four times per day (breakfast, lunch, dinner, and evening snack), 30 microg three times per day (breakfast, lunch and dinner [BLD]), 30 microg three times per day (breakfast, dinner and evening snack [BDS])…
Report a problemFND-0938941903
02HumanRandomized controlled trialEfficacy outcome
In patients with IDDM, pramlintide reduced mean daily plasma glucose versus placebo.
In plain wordsIn patients with IDDM, pramlintide reduced average daily blood glucose compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMean 24-h plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 microg four times per day · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Change in mean 24 h plasma glucose
−1.4 micromol/l
pramlintide 30 microg four times per day
Change in mean 24 h plasma glucose
0.3 micromol/l
placebo
Source sentences
Summary
After 4 weeks of pramlintide 30 microg four times per day administration, there was a statistically significant reduction in the mean 24 h plasma glucose concentration when compared to placebo (-1.4 +/- 0.5 vs 0.3 +/- 0.5 micromol/l, p = 0.009).
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial.
Summary · context
Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 microg four times per day (breakfast, lunch, dinner, and evening snack), 30 microg three times per day (breakfast, lunch and dinner [BLD]), 30 microg three times per day (breakfast, dinner and evening snack [BDS])…
Report a problemFND-0938941901
03HumanRandomized controlled trialSafety outcome
In patients with IDDM, nausea was the most frequent adverse event and subsided after the first treatment week in most patients.
In plain wordsIn patients with IDDM, nausea was the most frequent side effect with pramlintide and decreased after the first week in most patients.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
Nausea, the most frequent adverse event, subsided after the first week of treatment in the majority of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial.
Summary · context
Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 microg four times per day (breakfast, lunch, dinner, and evening snack), 30 microg three times per day (breakfast, lunch and dinner [BLD]), 30 microg three times per day (breakfast, dinner and evening snack [BDS])…
Report a problemFND-0938941904

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In patients with IDDM, serum fructosamine fell from baseline in all four pramlintide regimens and in the placebo group.
In plain wordsIn patients with IDDM, fructosamine fell from baseline with each pramlintide regimen and also with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum fructosamine
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fructosamine reduction
62 micromol/l
pramlintide 30 microg four times per day
Fructosamine reduction
43 micromol/l
pramlintide 30 microg three times per day (BLD)
Fructosamine reduction
47 micromol/l
pramlintide 30 microg three times per day (BDS)
Fructosamine reduction
46 micromol/l
pramlintide 60 microg twice per day
Fructosamine reduction
29 micromol/l
placebo
Source sentences
Summary
Serum fructosamine concentrations were reduced 62 +/- 10 micromol/l in the pramlintide 30 mg four times per day group, 43 +/- 7 micromol/l in the pramlintide 30 microg three times per day (BLD) group, 47 +/- 6 micromol/l in the pramlintide 30 microg three times per day (BDS) group, 46 +/- 7 micromol…
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial.
Summary · context
Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 microg four times per day (breakfast, lunch, dinner, and evening snack), 30 microg three times per day (breakfast, lunch and dinner [BLD]), 30 microg three times per day (breakfast, dinner and evening snack [BDS])…
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-0938941902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.